Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention. METHODS: To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 months. The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The key safety end point was major bleeding. RESULTS: The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81; 95% confidence interval [CI], 0.73 to 0.90; P<0.001). We also found significant reductions in the prasugrel group in the rates of myocardial infarction (9.7% for clopidogrel vs. 7.4% for prasugrel; P<0.001), urgent target-vessel revascularization (3.7% vs. 2.5%; P<0.001), and stent thrombosis (2.4% vs. 1.1%; P<0.001). Major bleeding was observed in 2.4% of patients receiving prasugrel and in 1.8% of patients receiving clopidogrel (hazard ratio, 1.32; 95% CI, 1.03 to 1.68; P=0.03). Also greater in the prasugrel group was the rate of life-threatening bleeding (1.4% vs. 0.9%; P=0.01), including nonfatal bleeding (1.1% vs. 0.9%; hazard ratio, 1.25; P=0.23) and fatal bleeding (0.4% vs. 0.1%; P=0.002). CONCLUSIONS: In patients with acute coronary syndromes with scheduled percutaneous coronary intervention, prasugrel therapy was associated with significantly reduced rates of ischemic events, including stent thrombosis, but with an increased risk of major bleeding, including fatal bleeding. Overall mortality did not differ significantly between treatment groups. (ClinicalTrials.gov number, NCT00097591 [ClinicalTrials.gov].)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients with ACS undergoing PCI, 12 months' DAPT with low-dose ASA and prasugrel or ticagrelor was superior to DAPT with clopidogrel in the diabetes sub-group of the respective RCTs, with a benefit-risk profile similar to the overall trial populations (Supplementary data online, Tables S12-13).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [310]
In the citing paper
“With prasugrel, the primary efficacy endpoint occurred in 9.9% of patients as compared with 12.1% receiving clopidogrel (HR 0.81, 95% CI 0.73-0.90;P , 0.001).The risk of major bleeding was increased with prasugrel.501”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
In the citing paper
“With ticagrelor given for 12 months the composite endpoint of death from vascular causes, myocardial infarction, or stroke occurred in 9.8% as compared with 11.7% of those receiving clopidogrel (HR 0.84, 95% CI 0.77-0.92;P , 0.001).No significant difference in rate of major bleeding was found.501 -503”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
In the citing paper
“In patients with ACS for whom an early invasive strategy is planned, dual antiplatelet therapy with a P2Y12 inhibitor (ticagrelor or prasugrel) added to aspirin was superior to clopidogrel and aspirin.”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
Citations
Cites
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Antman, E. M., Cohen, M., Bernink, P. J. L. M., McCabe, C. H., Horacek, T., Papuchis, G., Mautner, B., Corbalan, R., Radley, D., & Braunwald, E. (2000) · JAMA · doi:10.1001/jama.284.7.835 · Cited by 3,242
Self-citationSteinhubl, S. R., Berger, P. B., Mann III, J. T., Fry, E. T. A., DeLago, A., Wilmer, C., Topol, E. J., & for the CREDO Investigators (2002) · JAMA · doi:10.1001/jama.288.19.2411 · Cited by 3,078
Diener, H.-C., Bogousslavsky, J., Brass, L. M., Cimminiello, C., Csiba, L., Kaste, M., Leys, D., Matias-Guiu, J., & Rupprecht, H.-J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16721-4 · Cited by 2,275
WRITING COMMITTEE MEMBERS, Smith, S. C., Feldman, T. E., Hirshfeld, J. W., Jacobs, A. K., Kern, M. J., King, S. B., Morrison, D. A., O’Neill, W. W., Schaff, H. V., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.170815 · Cited by 2,218
Self-citationSabatine, M. S., Cannon, C. P., Gibson, C. M., López-Sendón, J. L., Montalescot, G., Theroux, P., Claeys, M. J., Cools, F., Hill, K. A., Skene, A. M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050522 · Cited by 1,924
Self-citation(2005) · The Lancet · doi:10.1016/s0140-6736(05)67660-x · Cited by 1,858
Guidelines for Percutaneous Coronary Interventions
Silber, S., Albertsson, P., Avilés, F. F., Camici, P. G., Colombo, A., Hamm, C., Jørgensen, E., Marco, J., Nordrehaug, J.-E., Ruzyllo, W., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi138 · Cited by 1,609
Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents
Mauri, L., Hsieh, W.-H., Massaro, J. M., Ho, K. K. L., D'Agostino, R., & Cutlip, D. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067731 · Cited by 1,441
Research works printed but not linked: 1
- Varenhorst C, 2007, Eur Heart J, 28, 189
Cited by
Items 901–1,000 of 1,004
Capodanno, D., & Angiolillo, D. J. (2020) · Circulation · doi:10.1161/circulationaha.120.045465 · Cited by 65
Ozaki, Y., Tobe, A., Onuma, Y., Kobayashi, Y., Amano, T., Muramatsu, T., Ishii, H., Yamaji, K., Kohsaka, S., Ismail, T. F., et al. (2024) · Cardiovascular Intervention and Therapeutics · doi:10.1007/s12928-024-01036-y · Cited by 69
“Prasugrel and ticagrelor reduce ischemic events and mortality in ACS patients compared to clopidogrel and are recommended by the current guidelines [23, 24, 52].”
BackgroundThe Antiplatelet Effect of Higher Loading and Maintenance Dose Regimens of Clopidogrel
Gladding, P. A., Webster, M. W. I., Zeng, I. S. L., Farrell, H., Stewart, J. T., Ruygrok, P., Ormiston, J., El‐Jack, S., Armstrong, G., Kay, P., et al. (2008) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2008.09.005 · Cited by 57
Perioperatives Management von Patienten mit Koronarstents bei nichtherzchirurgischen Eingriffen
Jámbor, C., Spannagl, M., & Zwißler, B. (2009) · Der Anaesthesist · doi:10.1007/s00101-009-1628-7 · Cited by 58
Nylander, S., Wågberg, F., Andersson, M., Skärby, T., & Gustafsson, D. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13027 · Cited by 57
Ancrenaz, V., Daali, Y., Fontana, P., Besson, M. J., Samer, C. F., Dayer, P., & Desmeules, J. A. (2010) · Current Drug Metabolism · doi:10.2174/138920010794233521 · Cited by 57
“The phase III study TRITON-TIMI 38 recently evaluated prasugrel in patients with ACS [20].”
Bertoluci, M. C., Moreira, R. O., Faludi, A. Á., Izar, M. C. D. O., Schaan, B. D., Valério, C. M., Bertolami, M. C., Chacra, A. P. M., Malachias, M. V. B., Vencio, S. A. C., et al. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0251-z · Cited by 69
Baber, U., Chandrasekhar, J., Sartori, S., Aquino, M. B., Kini, A. S., Kapadia, S. R., Weintraub, W. S., Muhlestein, J. B., Vogel, B., Faggioni, M., et al. (2017) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2017.02.047 · Cited by 57
“The TRITON-TIMI-38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction-38) study showed similar relative risk reductions in the primary MACE endpoint with prasugrel versus clopidogrel in patients with and without CKD (22).”
Tuteja, S., Glick, H. A., Matthai, W., Nachamkin, I., Nathan, A. S., Monono, K., Carcuffe, C., Maslowski, K., Chang, G., Kobayashi, T., et al. (2020) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.119.002640 · Cited by 66
Menichelli, M., Neumann, F., Ndrepepa, G., Mayer, K., Wöhrle, J., Bernlochner, I., Richardt, G., Witzenbichler, B., Sibbing, D., Gewalt, S., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-1806 · Cited by 58
Self-citationChen, W., Ni, M., Huang, H., Cong, H., Fu, X., Gao, W. D., Yang, Y., Yu, M., Song, X., Liu, M., et al. (2023) · MedComm · doi:10.1002/mco2.438 · Cited by 64
Review: Platelet Function Testing and Implications for Clinical Practice
Collet, J., & Montalescot, G. (2009) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248409339309 · Cited by 59
“Prasugrel is an oral, irreversible, third-generation thienopyridine that was approved in Europe in 2009 based on evidence from the TRITON trial, which demonstrated the improved clinical efficacy of prasugrel vs clopidogrel at the expense of excess bleeding in patients with ACS undergoing PCI.(33) In the subgroup of pa…”
MethodInfluentialSelf-citationWang, X., Dai-fu, Z., Zhuang, S., & Lai, Y. (2011) · Clinical Cardiology · doi:10.1002/clc.20884 · Cited by 56
Platelet Function Profiles in Patients with Diabetes Mellitus
Rollini, F., Franchi, F., Muñiz‐Lozano, A., & Angiolillo, D. J. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-013-9449-0 · Cited by 61
“Moreover, the occurrence of definite or probable stent thrombosis was reduced by ticagrelor treatment in the subgroup of patients undergoing PCI (2.2 vs. 2.9 %; HR=0.75; p=0.02).”
InfluentialTrenk, D., Schrör, K., Gawaz, M., Kristensen, S. D., Storey, R. F., Huber, K., Siller-Matula, J. M., & for the European Platelet Academy (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-03-0238 · Cited by 63
Wu, A. H. B. (2011) · Clinical Proteomics · doi:10.1186/1559-0275-8-12 · Cited by 56
Nikolsky, E., Mehran, R., Dangas, G., Yu, J., Parise, H., Xu, K., Pocock, S., & Stone, G. W. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.10.046 · Cited by 58
The Role of P2Y12 Receptor and Activated Platelets During Inflammation
Liverani, E., Kilpatrick, L. E., Tsygankov, A. Y., & Kunapuli, S. P. (2014) · Current Drug Targets · doi:10.2174/1389450115666140519162133 · Cited by 61
“However, prasugrel, while able to decrease the risk of myocardial infarction and stroke more efficiently, caused a significant increase in major and fatal bleeding, suggesting that it needs to be used cautiously [93].”
BackgroundVora, A. N., Wang, T. Y., Hellkamp, A. S., Thomas, L. E., Henry, T. D., Goyal, A., & Roe, M. T. (2016) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.002312 · Cited by 56
Li, Y., Wang, Y.-C., Wang, Y., Liu, J., Lee, C., Chen, C., Hsieh, C., Kuo, F. Y., Huang, W., Sung, S., et al. (2018) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.06.002 · Cited by 59
Martin, J., Williams, A. K., Klein, M. D., Sriramoju, V., Madan, S., Rossi, J. S., Clarke, M. M., Cicci, J. D., Cavallari, L. H., Weck, K. E., et al. (2019) · Genetics in Medicine · doi:10.1038/s41436-019-0611-1 · Cited by 59
microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring
Krammer, T. L., Mayr, M., & Hackl, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103477 · Cited by 59
Yasuda, H., Yamada, M., Sawada, S., Endo, Y., Inoue, K., Asano, F., Takeyama, Y., & Yoshiba, M. (2009) · Internal Medicine · doi:10.2169/internalmedicine.48.2031 · Cited by 56
“In addition, it is worthy to note that prasugrel, a novel thienopyridine derivative, is as effective as clopidgrel for the prevention of ischemic events (23, 24).”
BackgroundPeri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention
Kereiakes, D. J., & Gurbel, P. A. (2008) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2008.01.005 · Cited by 56
Angiolillo, D. J. (2007) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200707060-00005 · Cited by 56
Danchin, N., Lettino, M., Zeymer, U., Widimský, P., Bardajı́, A., Barrabés, J. A., Cequier, A. R., Claeys, M. J., Luca, L. D., Dörler, J., et al. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw003 · Cited by 55
Self-citationUpdate on Antithrombotic Therapy after Percutaneous Coronary Intervention
Saito, Y., & Kobayashi, Y. (2019) · Internal Medicine · doi:10.2169/internalmedicine.3685-19 · Cited by 57
“03) at 15 months compared to clopidogrel therapy in patients with ACS in the TRITON-TIMI 38 study (66).”
BackgroundTicagrelor or Prasugrel in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes
Valina, C. M., Neumann, F., Menichelli, M., Mayer, K., Wöhrle, J., Bernlochner, I., Aytekin, A., Richardt, G., Witzenbichler, B., Sibbing, D., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.584 · Cited by 63
Self-citationTucker, B., Vaidya, K., Cochran, B. J., & Patel, S. (2021) · Cells · doi:10.3390/cells10061391 · Cited by 72
“Preprocedural statin and anti-platelet loading has been shown to effectively reduce the rate of periprocedural MI and future MACE—an effect which is mediated, at least in part, by the anti-inflammatory effect of these agents [116,159,160].”
BackgroundContemporary use of glycoprotein IIb/IIIa inhibitors
Würtz, M., Grove, E. L., Caterina, R., Huber, K., Moliterno, D. J., Neumann, F., & Kristensen, S. D. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-07-0468 · Cited by 59
“Both have proved superior to clopidogrel in TRITON-TIMI 38 (50) and PLATO (51), respectively, and a TRITON-TIMI 38 substudy showed that the superiority of prasugrel was independent of the periprocedural use of GPI (52).”
Self-citationBeyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor
Giorgi, M. A., Arazi, H. C., González, C. D., & Girolamo, G. D. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.550573 · Cited by 56
“At the same time, the existence of a more potent and fastacting alternative brought along a challenge at the time of choosing the best treatment for patients with an ACS [43].”
BackgroundMethodRiesmeyer, J. S., Salazar, D. E., Weerakkody, G. J., Ni, L., Wrishko, R. E., Ernest, C. S., Luo, J., Li, Y. G., Small, D. S., Rohatagi, S., et al. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011406280 · Cited by 55
“Baseline characteristics for all prasugrel-treated patients in TRITON-TIMI 38 and those enrolled in the PK substudy were previously published.(4,8) Table I shows the primary composite efficacy end point and the rate of TIMI major or minor bleeding for these patients.”
BackgroundMethodResultInfluentialSelf-citationUrban, P. M., Abizaid, A., BANNING, A. P., Bartorelli, A. L., Baux, A. C., Džavík, V., Ellis, S. G., Gao, R., Holmes, D. R., Jeong, M. H., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.028 · Cited by 54
Self-citationPrasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
Gersh, B. J. (2008) · Yearbook of Cardiology · doi:10.1016/s0145-4145(08)04054-9 · Cited by 55
Therapeutic strategies for atherosclerosis and atherothrombosis: Past, present and future
Weber, C., Badimón, L., Mach, F., & van der Vorst, E. P. C. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-10-0814 · Cited by 60
“The TRITON-TIMI 38 trial compared prasugrel with clopidogrel and reported a significant reduction of cardiovascular events in patients treated with prasugrel, although an increased bleeding risk was observed in this group (49).”
MethodFaludi, A., Izar, M., Saraiva, J., Bianco, H. T., Chacra, A., Bertoluci, M., Moreira, R., Turatti, L., Bertolami, A., Sulzbach, M. L., et al. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170188 · Cited by 107
Mahla, E., Tantry, U. S., Prüller, F., & Gurbel, P. A. (2018) · Circulation · doi:10.1161/circulationaha.118.035160 · Cited by 58
Pharmacogenetic Testing for Clopidogrel Using the Rapid INFINITI Analyzer
Gladding, P. A., White, H. D., Voss, J., Ormiston, J., Stewart, J. T., Ruygrok, P., Bvaldivia, B., Baak, R., White, C., & Webster, M. W. I. (2009) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2009.08.018 · Cited by 55
Chin, C. T., Wang, T. Y., Anstrom, K. J., Zhu, B., Maa, J., Messenger, J. C., Ryan, K. A., Davidson-Ray, L. D., Zettler, M. E., Effron, M. B., et al. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.08.021 · Cited by 54
Varenhorst, C., Jensevik, K., Jernberg, T., Sundstrom, A., Hasvold, P., Held, C., Lagerqvist, B., & James, S. K. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht438 · Cited by 61
Antithrombotic Management of Elderly Patients With Coronary Artery Disease
Capranzano, P., & Angiolillo, D. J. (2021) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2021.01.040 · Cited by 60
Diabetes mellitus type 2 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Sukhareva, O. Y., Galstyan, G. R., Tokmakova, A. Y., Nikonova, T. V., Surkova, E. V., Кононенко, И. В., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12507 · Cited by 69
Platelet Abnormalities in CKD and Their Implications for Antiplatelet Therapy
Baaten, C. C. F. M. J., Schröer, J. R., Flöge, J., Marx, N., Jankowski, J., Berger, M., & Noels, H. (2022) · RWTH Publications (RWTH Aachen) · Cited by 54
The State of Periprocedural Antiplatelet Therapy After Recent Trials
Desai, N. R., & Bhatt, D. L. (2010) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2010.04.008 · Cited by 54
Nawarskas, J. J., & Clark, S. M. (2011) · Cardiology in Review · doi:10.1097/crd.0b013e3182099d86 · Cited by 57
Chintala, M. S., Shimizu, K., Ogawa, M., Yamaguchi, H., Doi, M., & Pk, J. (2008) · Journal of Pharmacological Sciences · doi:10.1254/jphs.08r06fm · Cited by 54
Bell, A., Roussin, A., Cartier, R., Chan, W., Douketis, J. D., Gupta, A. K., Kraw, M. E., Lindsay, T. F., Love, M. P., Pannu, N., et al. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2010.12.033 · Cited by 74
Shivaraju, A., Patel, V., Fonarow, G. C., Xie, H. W., Shroff, A. R., & Vidovich, M. I. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.09.009 · Cited by 54
Andersson, C., Lyngbæk, S., Nguyen, C. D., Nielsen, M. R. I., Gislason, G., Køber, L., & Torp-Pedersen, C. T. (2012) · JAMA · doi:10.1001/2012.jama.10779 · Cited by 55
New antithrombotic agents—insights from clinical trials
Paikin, J. S., Eikelboom, J. W., Cairns, J. A., & Hirsh, J. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.101 · Cited by 58
Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice
Muñiz‐Lozano, A., Rollini, F., Franchi, F., & Angiolillo, D. J. (2013) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944713487781 · Cited by 58
Bangalore, S., Singh, A., Toklu, B., DiNicolantonio, J. J., Croce, K., Feit, F., & Bhatt, D. L. (2014) · Open Heart · doi:10.1136/openhrt-2014-000068 · Cited by 55
“Although the newer agents prasugrel and ticagrelor reduce MACE in randomised trials, these agents increase bleeding in patients with PCI and cost significantly more than generic clopidogrel.(23) 24 Cilostazol, a phosphodiesterase III inhibitor, exhibits antiplatelet effects by increasing cAMP within platelets, and is…”
BackgroundStone, G. W. (2008) · Circulation · doi:10.1161/circulationaha.107.756494 · Cited by 67
Woods, L. T., Forti, K. M., Shanbhag, V., Camden, J. M., & Weisman, G. A. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114406 · Cited by 57
FILIPPO, O. D., D’Ascenzo, F., Raposeiras‐Roubín, S., Abu‐Assi, E., Peyracchia, M., Bocchino, P. P., Kinnaird, T. D., Ariza‐Solé, A., Liebetrau, C., Manzano‐Fernández, S., et al. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz048 · Cited by 53
Thomas, C., Cayla, G., Frère, C., Quilici, J., Poyet, R., Gaborit, B., Bali, L., Morange, P., Alessi, M., & Bonnet, J. (2009) · EuroIntervention · doi:10.4244/eijv5i3a51 · Cited by 53
Personalised antiplatelet therapies for coronary artery disease: what the future holds
Capodanno, D., & Angiolillo, D. J. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad362 · Cited by 58
Gremmel, T., Frelinger, A. L., & Michelson, A. D. (2024) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0044-1786387 · Cited by 65
Ernest, C. S., Small, D. S., Rohatagi, S., Salazar, D. E., Wallentin, L. C., Winters, K. J., & Wrishko, R. E. (2008) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-008-9103-7 · Cited by 53
Ben‐Dor, I., Torguson, R., Scheinowitz, M., Li, Y., Delhaye, C., Wakabayashi, K., Maluenda, G., Syed, A. I., Collins, S. D., González, M. A., et al. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.01.016 · Cited by 53
Borah, B. J., Moriarty, J. P., Crown, W. H., & Doshi, J. A. (2013) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.13.89 · Cited by 61
Diretrizes Brasileiras de Antiagregantes Plaquetários e Anticoagulantes em Cardiologia
Filho, A. M. L., Azmus, A., Soeiro, A., Quadros, A., Avezum, Á., Marques, A., Franci, A., Manica, A., Volschan, A., de Paola, A., et al. (2013) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.2013s009 · Cited by 95
Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis
Cornelissen, I., Palmer, D., David, T., Wilsbacher, L. D., Concengco, C., Conley, P. B., Pandey, A., & Coughlin, S. R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013309107 · Cited by 53
“Moreover, clopidogrel and related drugs that irreversibly block P2RY12 function prevent and treat arterial thrombosis but cause bleeding (2, 10), and PAR1 antagonists are being studied as an adjunct to standard antithrombotic treatment that includes P2RY12 inhibition (3, 4).”
BackgroundResultWillis, P., & Voeltz, M. D. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.06.013 · Cited by 53
Antiplatelet drug interactions with proton pump inhibitors
Scott, S. A., Obeng, A. O., & Hulot, J. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.856883 · Cited by 61
“However, this is balanced by an increased risk in major bleeding complications compared to clopidogrel, including fatal bleeding [32].”
BackgroundGrześk, G., Koziński, M., Navarese, E. P., Krzyżanowski, M., Grześk, E., Kubica, A., Siller-Matula, J. M., Castriota, F., & Kubica, J. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2011.12.029 · Cited by 55
“Both prasugrel and ticagrelor posses similar antiplatelet potency and more effectively than clopidogrel reduce the risk of subsequent myocardial infarction and stent thrombosis [4,5].”
BackgroundCardiovascular Disease in the Elderly
Jackson, C. F., & WENGER, N. K. (2011) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2011.05.003 · Cited by 78
Current therapies and investigational drugs for peripheral arterial disease
Suzuki, J.-I., Shimamura, M., Suda, H., Wakayama, K., Kumagai, H., Ikeda, Y., Akazawa, H., Isobe, M., Komuro, I., & Morishita, R. (2015) · Hypertension Research · doi:10.1038/hr.2015.134 · Cited by 56
Aradi, D., Groß, L., Trenk, D., Geisler, T., Merkely, B. P., Kiss, R. G., Komócsi, A., Dézsi, C. A., Ruzsa, Z., Ungi, I., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz202 · Cited by 60
Self-citationKarathanos, A., Lin, Y., Dannenberg, L., Parco, C., Schulze, V., Brockmeyer, M., Jung, C., Heinen, Y., Perings, S. M., Zeymer, U., et al. (2019) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.05.003 · Cited by 55
Podlasek, A., Sultan, A. S. A., Assis, Z., Kashani, N., Goyal, M., & Almekhlafi, M. (2019) · Journal of NeuroInterventional Surgery · doi:10.1136/neurintsurg-2019-014996 · Cited by 53
Angiolillo, D. J., Suryadevara, S., Capranzano, P., & Bass, T. A. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.16.2893 · Cited by 53
“A total of 56 patients were randomized, of which 37 underwent PCI.”
BackgroundMethodInfluentialAntiplatelet drug nonresponsiveness
Gladding, P. A., Webster, M. W. I., Ormiston, J., Olsen, S., & White, H. D. (2008) · American Heart Journal · doi:10.1016/j.ahj.2007.12.034 · Cited by 53
“Thrombin is the most potent agonist of platelet activation, and despite blockade of antiplatelet pathwayswith aspirin and clopidogrel, persistent thrombin generation poses a considerable continued stimulus for platelets.(14) Blocking the platelet protease-activated receptor 1 leaves other thrombin-mediated hemostatic…”
BackgroundAcute management of unstable angina and non-ST segment elevation myocardial infarction
Morita, F., Pesaro, A. E. P., Franken, M., & Wajngarten, M. (2015) · Einstein (São Paulo) · doi:10.1590/s1679-45082015rw3172 · Cited by 59
Rosselló, X., Bueno, H., Pocock, S., de Werf, F. V., Danchin, N., Annemans, L., Medina, J., & Zeymer, U. (2018) · Clinical Cardiology · doi:10.1002/clc.23116 · Cited by 55
“Data from randomized clinical trials show substantially lower mortality rates in the first year after the index MI.(19,20) For example, in the Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of AspirinThrombolysis in Myocardial Infarction 54…”
MethodInfluentialNguyen, A. B., Cavallari, L. H., Rossi, J. S., Stouffer, G. A., & Lee, C. R. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.991646 · Cited by 54
“Outcomes by Optimizing Platelet Inhibition with Prasugrel– Thrombolysis in Myocardial Infarction (TRITON–TIMI) 38 and Study of Platelet Inhibition and Patient Outcomes (PLATO) randomized clinical trials, prasugrel and ticagrelor displayed superior efficacy compared to clopidogrel in acute coronary syndrome (ACS) patie…”
BackgroundMethodBhatia, K., Ladd, L., Carr, K., Napoli, M. D., Saver, J. L., McCullough, L. D., Farahabadi, M. H., Alsbrook, D. L., Hinduja, A., Ortiz-Garcia, J., et al. (2023) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-023-01266-2 · Cited by 63
Atherogenesis and atherothrombosis – focus on diabetes mellitus
Stratmann, B., & Tschoepe, D. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.12.004 · Cited by 59
Valgimigli, M. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.08.013 · Cited by 52
Warner, T. D., Armstrong, P. C. J., Curzen, N. P., & Mitchell, J. A. (2010) · Heart · doi:10.1136/hrt.2010.205724 · Cited by 57
“receptor antagonists—notably prasugrel and ticagrelor—have all been conducted in the presence of aspirin.”
BackgroundSharma, R., Reddy, Singh, V. N., Sharma, Voelker, & Bhatt, D. L. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s6787 · Cited by 48
“New drugs on the horizon Other drugs on the horizon include a new thienopyridines agent (prasugrel) which has been evaluated in several large scale trials.(51,52) In these studies, a loading dose of 60 mg and maintenance dose of 10 mg of prasugrel produced more consistent platelet inhibition compared to clopidogrel wi…”
Chan, M. Y., Mahaffey, K. W., Sun, L. J., Pieper, K. S., White, H. D., Aylward, P. E., Ferguson, J. J., Califf, R. M., & Roe, M. T. (2008) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2008.03.019 · Cited by 52
Merriweather, N., & Sulzbach, L. M. (2012) · Critical Care Nurse · doi:10.4037/ccn2012123 · Cited by 66
Totani, L., Dell’Elba, G., Martelli, N., Santo, A. D., Piccoli, A. L., Jr., Amore, C., & Evangelista, V. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-12-0867 · Cited by 53
“The greater inhibition of platelet activation may explain the overall reduction in ischaemic events with prasugrel compared to clopidogrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention (PCI) recruited in the TRITON-TIMI-38 trial (3, 4).”
BackgroundCaroff, E., Hubler, F., Meyer, E. A., Renneberg, D., Gnerre, C., Treiber, A., Rey, M., Hess, P., Steiner, B., Hilpert, K., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00933 · Cited by 52
Adelborg, K., Grove, E. L., Sundbøll, J., Laursen, M., & Schmidt, M. (2016) · Heart · doi:10.1136/heartjnl-2016-309402 · Cited by 57
Deiman, B. A. L. M., Tonino, P. A. L., Kouhestani, K., Schrover, C., Scharnhorst, V., Dekker, L., & Pijls, N. H. J. (2016) · Netherlands Heart Journal · doi:10.1007/s12471-016-0873-z · Cited by 52
“This difference in incremental cost-effectiveness ratio between prasugrel and ticagrelor was previously explained by the increase of fatal bleeding when using prasugrel [12, 14, 15].”
MethodSchiele, F., Ecarnot, F., & Chopard, R. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317706586 · Cited by 60
Diabetes and antiplatelet therapy: from bench to bedside
Rios, J. R. R., Franchi, F., Rollini, F., & Angiolillo, D. J. (2018) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2018.05.09 · Cited by 59
Modern Management of ST-Segment Elevation Myocardial Infarction
Frampton, J., DeVries, J. T., Welch, T. D., & Gersh, B. J. (2018) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2018.08.005 · Cited by 55
Huo, Y., Jeong, Y., Gong, Y., Wang, D. W., He, B., Chen, J., Fu, G., Chen, Y., Li, J., Li, Y., et al. (2018) · 中国科学通报:英文版 · doi:10.1016/j.scib.2018.12.020 · Cited by 55
“Prasugrel was studied at the dose of 10 mg daily for clinical usage in a phase III study [25], and 10 mg was later recommended as the maintenance dose in its drug instructions in USA and Europe.”
Backgroundvan Leeuwen, M. A. H., van der Hoeven, N. W., Janssens, G. N., Everaars, H., Nap, A., Lemkes, J. S., de Waard, G. A., van de Ven, P. M., van Rossum, A. C., Ten Cate, T. J. F., et al. (2019) · doi:10.7892/boris.124089 · Cited by 52
Nakamura, M., Kadota, K., Takahashi, A., Kanda, J., Anzai, H., Ishii, Y., Shibata, Y., Yasaka, Y., Takamisawa, I., Yamaguchi, J., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015439 · Cited by 52
Shin, D., Kang, H., Jang, J., Moon, K., Song, Y. B., Park, D., Bae, J., Kim, J., Hur, S., Kim, B. O., et al. (2019) · Korean Circulation Journal · doi:10.4070/kcj.2018.0413 · Cited by 52
Do Current Clinical Trials Meet Society’s Needs?
Pocock, S., & Gersh, B. J. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.08.008 · Cited by 51
French, S. L., Arthur, J. F., Tran, H. A., & Hamilton, J. R. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.10.006 · Cited by 51
“How does vorapaxar compare with other antithrombotic agents? Several large-scale clinical trials have been conducted to determine the optimal anti-thrombotic management of ACS patients, including studies on the anti-platelet drugs aspirin, clopidogrel [13,14], prasugrel [92], and ticagrelor [93], as well as anticoagul…”
BackgroundTriple Therapy for Atrial Fibrillation and Percutaneous Coronary Intervention
Dewilde, W. J. M., Janssen, P. W. A., Verheugt, F. W. A., Storey, R. F., Adriaenssens, T., Hansen, M. L., Lamberts, M., & ten Berg, J. M. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.06.1193 · Cited by 53
Li, B. X., Dai, X., Xu, X., Adili, R., Neves, M. A. D., Lei, X., Shen, C., Zhu, G., Wang, Y., Zhou, H. C., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91165-8 · Cited by 60
Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention
Galli, M., Laborante, R., Andreotti, F., Vergallo, R., Montone, R. A., Iaconelli, A., Trani, C., Burzotta, F., Crea, F., & D’Amario, D. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2308286 · Cited by 62
“Prasugrel and ticagrelor are characterized by more potent and predictable pharmacodynamic effects compared with clopidogrel, which however lead to an increased risk of bleeding [105,106].”
BackgroundCohen, M. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.2.149 · Cited by 25
Metadata
- Authors
- Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., Riesmeyer, J., Weerakkody, G., Gibson, C. M., & Antman, E. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Inserm (FR)
- Bikur Cholim Hospital (IL)
- Universitäts-Herzzentrum Freiburg-Bad Krozingen (DE)
- Ospedale di Parma (IT)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2001-2015
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2169387542
- Cited by
- 6,790
- References
- 40
- Citations by year
- 2026: 162 · 2025: 202 · 2024: 187 · 2023: 265 · 2022: 309 · 2021: 326 · 2020: 339 · 2019: 361 · 2018: 389 · 2017: 418 · 2016: 419 · 2015: 465 · 2014: 448 · 2013: 502 · 2012: 507
- FWCI
- 238.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- prasugrel, clopidogrel, acute coronary syndrome, percutaneous coronary intervention, dual antiplatelet therapy, thienopyridines, major bleeding, stent thrombosis, myocardial infarction, target vessel revascularization, cardiovascular mortality, bleeding risk stratification, bleeding risk score
- MeSH terms
- Prasugrel Hydrochloride, Clopidogrel, Aged, Aspirin, Double-Blind Method, Drug Therapy, Combination, Female, Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Piperazines, Platelet Aggregation Inhibitors, Prodrugs, Thiophenes, Thrombosis, Ticlopidine, Angioplasty, Balloon, Coronary, Stroke, Kaplan-Meier Estimate, Acute Coronary Syndrome, Purinergic P2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.